Market access challenges in the EU for high medical value diagnostic tests

Personalized Medicine

Volumn 8, Issue 2, 2011, Pages 137-148

  Miller, Iain ^a,b   Ashton Chess, Joanna ^a,c   Spolders, Herman ^a,d   Fert, Vincent ^a,e   Ferrara, Joseph ^f   Kroll, Werner ^a,g   Askaa, Jon ^h   Larcier, Patrick ^c   Terry, Patrick F ^a,i   Bruinvels, Anne ^j   Huriez, Alain ^a,c  

^a European Personalised Medicine Association   (France)

^b BIOMÉRIEUX   (France)

^c TcLand Expression   (France)

^d Biotech Management Consultancy   (Belgium)

^e IPSOGEN   (France)

^f Boston Healthcare Associates Inc   (United States)

^g Novartis Molecular Diagnostics LLC   (United States)

^h Medical Prognosis Institute   (Denmark)

ⁱ Scientia Advisors   (United States)

^j Elixior Ltd   (United Kingdom)

more..

Author keywords

EU; high value; personalized medicine; reimbursement

Indexed keywords

ARTICLE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; ECONOMIC ASPECT; EUROPEAN UNION; FUNDING; HEALTH CARE ACCESS; INVESTMENT; PRIORITY JOURNAL; REIMBURSEMENT; UNITED STATES;

EID: 79952610995     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.11.2     Document Type: Article

References (9)

1. Cowen & Co: Therapeutic Categories Outlook, 2008-2012 estimate. Cowen Group, NY, USA (2008).
2. Shankaran V, Luu TH, Nonzee N et al.: Cost-effectiveness of a healthcare provider-directed intervention to promote colorectal cancer screening. J. Clin. Oncol. 27(15S) (2009) (Abstract 6583).
3. William Blair & Company: Equity research report. William Blair & Company, IL, USA (2010).
4. Hornberger J, Cosler LE, Lyman GH: Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am. J. Manag. Care 11(5), 313-324 (2005). (Pubitemid 40646936)
5. Reimbursement workshop jointly organized by European Device Manufacturers association (EDMA) and International Association of Clinical Chemistry and Laboratory Medicine (IFCC). Brussels, Belgium, 26 November 2010.
6. Spear BB, Heath-Chiozzi M, Huff J: Clinical Application of Pharmacogenetics. Trends Mol. Med. 7(5), 201-204 (2001). (Pubitemid 32822891)
7. Ernst FR, Grizzle AJ: Drug-related morbidity and mortality: updating the cost-of-illness model. J. Am. Pharm. Assoc. 41, 192-199 (2001).
8. Market Access for Personalised Medicine in Europe. European Personalized Medicine Coalition webinar, 15 September 2010.
9. Poithier K, Gustavsen G: In Vivo Business and Medicine Report. F-D-C Reports, Inc. and Windhover Information; Elsevier Business Intelligence, NJ, USA (2009).